PRParmida Ranji

Parmida Ranji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Parmida Ranji has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Manish Rauthan

    Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden

    4 shared publications
  • Marc Pilon

    Department of Chemistry and Molecular Biology, University of Gothenburg , Gothenburg 405 30

    4 shared publications
  • Christophe Pitot

    Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden

    2 shared publications
  • Anders Ståhlberg

    Department of Laboratory Medicine, Sahlgrenska Center for Cancer Research, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    1 shared publication
  • Andreas Svanström

    Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, Sahlgrenska Cancer Center, University of Gothenburg, SE-41390, Gothenburg, Sweden

    1 shared publication
  • Anna Gustafsson

    Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Patient-derived scaffolds uncover breast cancer promoting properties of the microenvironment

    by Göran Landberg, Paul Fitzpatrick, Pauline Isakson, Emma Jonasson, Joakim Karlsson, Erik Larsson, Andreas Svanström, Svanheidur Rafnsdottir, Emma Persson, Anna Gustafsson, et al.


  • Open Access

    Caenorhabditis elegans PAQR-2 and IGLR-2 Protect against Glucose Toxicity by Modulating Membrane Lipid Composition

    by Emma Svensk, Ranjan Devkota, Marcus Ståhlman, Parmida Ranji, Manish Rauthan, Fredrik Magnusson, Sofia Hammarsten, Maja Johansson, Jan Borén, Marc Pilon

    In spite of the worldwide impact of diabetes on human health, the mechanisms behind glucose toxicity remain elusive. Here we show that C. elegans mutants lacking paqr-2, the worm homolog of the adiponectin receptors AdipoR1/2, or its newly identified functional partner iglr-2, are glucose intolerant and die in the presence of as little as 20 mM glucose. Using FRAP (Fluorescence Recovery After Photobleaching) on living worms, we found that cultivation in the presence of glucose causes a decrease in membrane fluidity in paqr-2 and iglr-2 mutants and that genetic suppressors of this sensitivity act to restore membrane fluidity by promoting fatty acid desaturation. The essential roles of paqr-2 and iglr-2 in the presence of glucose are completely independent from daf-2 and daf-16, the C. elegans homologs of the insulin receptor and its downstream target FoxO, respectively. Using bimolecular fluorescence complementation, we also show that PAQR-2 and IGLR-2 interact on plasma membranes and thus may act together as a fluidity sensor that controls membrane lipid composition. Using the nematode C. elegans as a model, we show that glucose decreases the fluidity of cellular membranes, which suggests a novel mechanism for the glucose toxicity observed in diabetics. We also show that the membrane proteins PAQR-2 and IGLR-2 are located together on cellular membranes and regulate fluidity in the presence of glucose. This is an important finding because PAQR-2 is a worm homolog of AdipoR1 and AdipoR2, themselves important anti-diabetic proteins of which the cellular mechanism of action has been difficult to elucidate. Thus in one stroke our work may explain glucose toxicity, describes a cellular mechanism that counteracts it, helps clarify the anti-diabetic roles of AdipoR1/2, and identifies IGLR-2 as a PAQR-2 co-receptor.


  • Open Access

    A Mutation in Caenorhabditis elegans NDUF-7 Activates the Mitochondrial Stress Response and Prolongs Lifespan via ROS and CED-4

    by Manish Rauthan, Parmida Ranji, Ragda Abukar, Marc Pilon

    The mevalonate pathway is responsible for the synthesis of cholesterol, coenzyme Q, prenyl groups essential for small GTPase modification and function, and for the production of dolichols important for protein glycosylation. Statins, i.e. cholesterol-lowering drugs that inhibit the rate-limiting enzyme in the mevalonate pathway, HMG-CoA reductase, are lethal to Caenorhabditis elegans even though this animal lacks the branch of the mevalonate pathway that leads to cholesterol synthesis. To better understand the effects of statins that are not related to cholesterol we have adopted the strategy of isolating statin-resistant C. elegans mutants. Previously, we showed that such mutants often have gain-of-function mutations in ATFS-1, a protein that activates the mitochondrial unfolded protein response. Here, we describe the isolation of a statin-resistant mutant allele of the NDUF-7 protein, which is a component of complex I in the mitochondrial electron transport chain. The novel nduf-7(et19) mutant also exhibits constitutive and ATFS-1-dependent activation of the mitochondrial unfolded protein response (UPRmt) and prolonged life span, both of which are mediated through production of ROS. Additionally, lifespan extension, but not activation of the mitochondrial unfolded protein response, was dependent on the pro-apoptotic gene ced-4. We conclude that the nduf-7(et19) mutant allele causes an increase in reactive oxygen species that activate ATFS-1, hence UPRmt-mediated statin resistance, and extends life span via CED-4.


  • Open Access

    Loss of HMG-CoA Reductase in C. elegans Causes Defects in Protein Prenylation and Muscle Mitochondria

    by Parmida Ranji, Manish Rauthan, Christophe Pitot, Marc Pilon

    HMG-CoA reductase is the rate-limiting enzyme in the mevalonate pathway and the target of cholesterol-lowering statins. We characterized the C. elegans hmgr-1(tm4368) mutant, which lacks HMG-CoA reductase, and show that its phenotypes recapitulate that of statin treatment, though in a more severe form. Specifically, the hmgr-1(tm4368) mutant has defects in growth, reproduction and protein prenylation, is rescued by exogenous mevalonate, exhibits constitutive activation of the UPRer and requires less mevalonate to be healthy when the UPRmt is activated by a constitutively active form of ATFS-1. We also show that different amounts of mevalonate are required for different physiological processes, with reproduction requiring the highest levels. Finally, we provide evidence that the mevalonate pathway is required for the activation of the UPRmt.


  • Open Access

    The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway

    by Manish Rauthan, Parmida Ranji, Nataly Aguilera Pradenas, Christophe Pitot, Marc Pilon

    Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the synthesis of cholesterol via the mevalonate pathway. This pathway also produces coenzyme Q (a component of the respiratory chain), dolichols (important for protein glycosylation), and isoprenoids (lipid moieties responsible for the membrane association of small GTPases). We previously showed that the nematode Caenorhabditis elegans is useful to study the noncholesterol effects of statins because its mevalonate pathway lacks the sterol synthesis branch but retains all other branches. Here, from a screen of 150,000 mutagenized genomes, we isolated four C. elegans mutants resistant to statins by virtue of gain-of-function mutations within the first six amino acids of the protein ATFS-1, the key regulator of the mitochondrial unfolded protein response that includes activation of the chaperones HSP-6 and HSP-60. The atfs-1 gain-of-function mutants are also resistant to ibandronate, an inhibitor of an enzyme downstream of HMG-CoA reductase, and to gliotoxin, an inhibitor acting on a subbranch of the pathway important for protein prenylation, and showed improved mitochondrial function and protein prenylation in the presence of statins. Additionally, preinduction of the mitochondrial unfolded protein response in wild-type worms using ethidium bromide or paraquat triggered statin resistance, and similar observations were made in Schizosaccharomyces pombe and in a mammalian cell line. We conclude that statin resistance through maintenance of mitochondrial homeostasis is conserved across species, and that the cell-lethal effects of statins are caused primarily through impaired protein prenylation that results in mitochondria dysfunction.